Skip to main content
Erschienen in: Current Rheumatology Reports 5/2013

01.05.2013 | INFECTIONS AND ARTHRITIS (K WINTHROP, SECTION EDITOR)

Infectious Complications in Juvenile Idiopathic Arthritis

verfasst von: Andrew Hurd, Timothy Beukelman

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Many questions regarding the risk of infection associated with JIA and with the immunosuppressant therapeutic agents commonly used to treat JIA are currently unanswered. It appears likely that JIA itself increases the background rate of serious bacterial infections, irrespective of immunosuppressant use. The available evidence suggests that treatment with methotrexate or tumor necrosis factor inhibitors only modestly increases the risk of serious infections and may not increase the risk at all. Opportunistic infections are very uncommon among children with JIA, but they likely occur at an increased rate compared to children without JIA. Intra-articular glucocorticoid injections almost never result in infectious complications in the treatment of JIA when performed carefully. Additional controlled studies of the risks of infection among children with JIA are needed, particularly comparative studies of newer therapeutic agents.
Literatur
1.
Zurück zum Zitat Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2012;59(2):301–27. Epub 2012/05/09.CrossRef Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin N Am. 2012;59(2):301–27. Epub 2012/05/09.CrossRef
2.
Zurück zum Zitat Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49. Epub 2011/06/21.PubMedCrossRef Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49. Epub 2011/06/21.PubMedCrossRef
3.
Zurück zum Zitat Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82. Epub 2011/04/01.CrossRef Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82. Epub 2011/04/01.CrossRef
4.
Zurück zum Zitat Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867–74. Epub 2012/08/04.PubMedCrossRef Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39(9):1867–74. Epub 2012/08/04.PubMedCrossRef
5.
Zurück zum Zitat Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387–93. Epub 2008/02/09.PubMed Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387–93. Epub 2008/02/09.PubMed
6.
Zurück zum Zitat Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93. Epub 2002/10/02.PubMedCrossRef Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93. Epub 2002/10/02.PubMedCrossRef
7.
Zurück zum Zitat Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51 Suppl 5:v38–47. Epub 2012/06/29.PubMedCrossRef Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology. 2012;51 Suppl 5:v38–47. Epub 2012/06/29.PubMedCrossRef
8.
Zurück zum Zitat Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300. Epub 2002/10/02.PubMedCrossRef Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300. Epub 2002/10/02.PubMedCrossRef
9.
Zurück zum Zitat Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46(7):1157–60. Epub 2007/05/05.PubMedCrossRef Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46(7):1157–60. Epub 2007/05/05.PubMedCrossRef
10.
Zurück zum Zitat Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71(7):1128–33. Epub 2012/01/14.PubMedCrossRef Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71(7):1128–33. Epub 2012/01/14.PubMedCrossRef
11.
Zurück zum Zitat Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA: J Am Med Assoc. 2011;306(21):2331–9. Epub 2011/11/08.CrossRef Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA: J Am Med Assoc. 2011;306(21):2331–9. Epub 2011/11/08.CrossRef
12.
Zurück zum Zitat Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91. Epub 2011/02/04.PubMedCrossRef Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91. Epub 2011/02/04.PubMedCrossRef
13.
Zurück zum Zitat •• Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–80. Epub 2012/05/10. This study of administrative claims data demonstrated an increased background risk of serious bacterial infection among children with JIA, in the absence of systemic immunosuppressant therapy. This study also demonstrated no significant increased risk of infection associated with methotrexate or TNFi use, but did show a significant increased risk with high doses of oral glucocorticoids. PubMedCrossRef •• Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773–80. Epub 2012/05/10. This study of administrative claims data demonstrated an increased background risk of serious bacterial infection among children with JIA, in the absence of systemic immunosuppressant therapy. This study also demonstrated no significant increased risk of infection associated with methotrexate or TNFi use, but did show a significant increased risk with high doses of oral glucocorticoids. PubMedCrossRef
14.
Zurück zum Zitat • Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;[accepted for publication 27 Dec 2012]. This study of administrative claims data demonstrated an increased rate of opportunistic infections among children with JIA compared to children without JIA. • Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;[accepted for publication 27 Dec 2012]. This study of administrative claims data demonstrated an increased rate of opportunistic infections among children with JIA compared to children without JIA.
15.
Zurück zum Zitat Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev. 2012;11(5):297–300. Epub 2010/02/23.PubMedCrossRef Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev. 2012;11(5):297–300. Epub 2010/02/23.PubMedCrossRef
16.
Zurück zum Zitat Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res. 2010;62(6):800–4. Epub 2010/06/11.CrossRef Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res. 2010;62(6):800–4. Epub 2010/06/11.CrossRef
17.
Zurück zum Zitat Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 2010;62(11):3131–9. Epub 2010/07/28.PubMedCrossRef Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum. 2010;62(11):3131–9. Epub 2010/07/28.PubMedCrossRef
18.
Zurück zum Zitat • Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804. Epub 2009/08/29. This prospective, observational study revealed no significant difference in the rates of medically important infections among children with JIA treated with the combination of etanercept and methotrexate, or etanercept alone, or methotrexate alone. • Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794–804. Epub 2009/08/29. This prospective, observational study revealed no significant difference in the rates of medically important infections among children with JIA treated with the combination of etanercept and methotrexate, or etanercept alone, or methotrexate alone.
19.
Zurück zum Zitat • Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–25. Epub 2008/04/17. This prospective, observational study demonstrated no significant difference in the rate of serious infections among children with JIA treated with the combination of etanercept and methotrexate versus etanercept alone. • Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–25. Epub 2008/04/17. This prospective, observational study demonstrated no significant difference in the rate of serious infections among children with JIA treated with the combination of etanercept and methotrexate versus etanercept alone.
20.
Zurück zum Zitat Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504. Epub 2008/04/29.PubMedCrossRef Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504. Epub 2008/04/29.PubMedCrossRef
21.
Zurück zum Zitat Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51(8):1407–15. Epub 2012/03/27.PubMedCrossRef Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51(8):1407–15. Epub 2012/03/27.PubMedCrossRef
22.
Zurück zum Zitat Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106. Epub 2007/09/01.PubMedCrossRef Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106. Epub 2007/09/01.PubMedCrossRef
23.
Zurück zum Zitat Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–22. Epub 2010/03/20.PubMedCrossRef Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–22. Epub 2010/03/20.PubMedCrossRef
24.
Zurück zum Zitat Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. Epub 2008/08/22.PubMedCrossRef Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. Epub 2008/08/22.PubMedCrossRef
25.
Zurück zum Zitat Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine. 2011;90(2):139–45. Epub 2011/03/02.PubMedCrossRef Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine. 2011;90(2):139–45. Epub 2011/03/02.PubMedCrossRef
26.
Zurück zum Zitat Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401–6. Epub 2011/05/19.PubMedCrossRef Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401–6. Epub 2011/05/19.PubMedCrossRef
27.
Zurück zum Zitat Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res. 2012;64(10):1480–9. Epub 2012/07/27.CrossRef Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res. 2012;64(10):1480–9. Epub 2012/07/27.CrossRef
28.
Zurück zum Zitat Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91. Epub 2008/07/18.PubMedCrossRef Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91. Epub 2008/07/18.PubMedCrossRef
29.
Zurück zum Zitat Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802. Epub 2010/03/02.PubMedCrossRef Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802. Epub 2010/03/02.PubMedCrossRef
30.
Zurück zum Zitat Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23. Epub 2010/12/24.PubMedCrossRef Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23. Epub 2010/12/24.PubMedCrossRef
31.
Zurück zum Zitat Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine: Rev Rhum. 2011;78(3):279–84. Epub 2011/01/29.CrossRef Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine: Rev Rhum. 2011;78(3):279–84. Epub 2011/01/29.CrossRef
32.
Zurück zum Zitat Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39. Epub 2012/04/05.CrossRef Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–39. Epub 2012/04/05.CrossRef
33.
Zurück zum Zitat Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163(4):487–94. Epub 2003/02/18.PubMedCrossRef Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163(4):487–94. Epub 2003/02/18.PubMedCrossRef
34.
Zurück zum Zitat Dao KH, Herbert M, Habal N, Cush JJ. Nonserious infections: should there be cause for serious concerns? Rheum Dis Clin N Am. 2012;38(4):707–25. Epub 2012/11/10.CrossRef Dao KH, Herbert M, Habal N, Cush JJ. Nonserious infections: should there be cause for serious concerns? Rheum Dis Clin N Am. 2012;38(4):707–25. Epub 2012/11/10.CrossRef
35.
Zurück zum Zitat Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70(6):956–60. Epub 2011/02/03.PubMedCrossRef Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70(6):956–60. Epub 2011/02/03.PubMedCrossRef
36.
Zurück zum Zitat Scott C, Meiorin S, Filocamo G, Lanni S, Valle M, Martinoli C, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28(5):774–81. Epub 2010/09/25.PubMed Scott C, Meiorin S, Filocamo G, Lanni S, Valle M, Martinoli C, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28(5):774–81. Epub 2010/09/25.PubMed
37.
Zurück zum Zitat Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum. 1981;10(4):231–54. Epub 1981/05/01.PubMedCrossRef Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum. 1981;10(4):231–54. Epub 1981/05/01.PubMedCrossRef
38.
Zurück zum Zitat American Academy of Pediatrics. In: Pickering LK, editor. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012. American Academy of Pediatrics. In: Pickering LK, editor. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012.
39.
Zurück zum Zitat Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Kone-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–22. Epub 2011/09/08.PubMedCrossRef Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Kone-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–22. Epub 2011/09/08.PubMedCrossRef
40.
Zurück zum Zitat Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(2):639–46. Epub 2007/02/01.PubMedCrossRef Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(2):639–46. Epub 2007/02/01.PubMedCrossRef
41.
Zurück zum Zitat Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012;30(5):936–40. Epub 2011/12/06.PubMedCrossRef Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012;30(5):936–40. Epub 2011/12/06.PubMedCrossRef
42.
Zurück zum Zitat Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou-Gertsi P, Tritsoni M, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–13. Epub 2010/05/18.PubMedCrossRef Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou-Gertsi P, Tritsoni M, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–13. Epub 2010/05/18.PubMedCrossRef
43.
Zurück zum Zitat Toplak N, Subelj V, Kveder T, Cucnik S, Prosenc K, Trampus-Bakija A, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(3):436–44. Epub 2012/04/20.PubMed Toplak N, Subelj V, Kveder T, Cucnik S, Prosenc K, Trampus-Bakija A, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(3):436–44. Epub 2012/04/20.PubMed
44.
Zurück zum Zitat Erguven M, Kaya B, Hamzah OY, Tufan F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc: JCMA. 2011;74(5):205–8. Epub 2011/05/10.PubMedCrossRef Erguven M, Kaya B, Hamzah OY, Tufan F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc: JCMA. 2011;74(5):205–8. Epub 2011/05/10.PubMedCrossRef
45.
Zurück zum Zitat Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–73. Epub 2011/11/18.PubMedCrossRef Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–73. Epub 2011/11/18.PubMedCrossRef
46.
Zurück zum Zitat Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62(7):1034–9. Epub 2010/03/18.CrossRef Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62(7):1034–9. Epub 2010/03/18.CrossRef
47.
Zurück zum Zitat Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384–7. Epub 2007/02/08.PubMedCrossRef Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384–7. Epub 2007/02/08.PubMedCrossRef
48.
Zurück zum Zitat Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology. 2009;48(2):144–8. Epub 2008/12/17.PubMedCrossRef Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology. 2009;48(2):144–8. Epub 2008/12/17.PubMedCrossRef
49.
Zurück zum Zitat Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA: J Am Med Assoc. 2012;308(1):43–9. Epub 2012/07/05.CrossRef Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA: J Am Med Assoc. 2012;308(1):43–9. Epub 2012/07/05.CrossRef
Metadaten
Titel
Infectious Complications in Juvenile Idiopathic Arthritis
verfasst von
Andrew Hurd
Timothy Beukelman
Publikationsdatum
01.05.2013
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 5/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0327-1

Weitere Artikel der Ausgabe 5/2013

Current Rheumatology Reports 5/2013 Zur Ausgabe

INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTON EDITOR)

Update on Treatment of Inclusion Body Myositis

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Inhibition of Nitric Oxide and Antiphospholipid Antibody-Mediated Thrombosis

OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

Osteoarthritis and Osteoporosis: What Is the Overlap?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.